Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY

Next Previous
X
Search
Trial Profile

A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fordadistrogene-movaparvovec (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Pfizer

    • Most Recent Events

    • 09 Nov 2022 Results investigating the impact fordadistrogene movaparvovec on physical functioning based on the Pediatric Outcomes Data Collection Instrument (PODCI), presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 26 Apr 2022 Planned End Date changed from 30 May 2026 to 30 Mar 2026.
    • 30 Mar 2022 Planned End Date changed from 15 May 2028 to 30 May 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top